NeoGenomics Reports 38% increase in Revenue to a Record $23.2 Million and Adjusted EBITDA of $2.6 Million for the Third Quarter of 2014
Press Release
Read More
NeoGenomics is First to Offer Molecular Testing for Resistance to Bruton Tyrosin Kinase Inhibitors for Chronic Lymphocytic Leukemia
Press Release
Read More
NeoGenomics Launches 315 Gene Next Generation Sequencing Test for Solid Tumor Discovery Profiling
Press Release
Read More
Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the rationale and insight for Gleevec high-dose therapy study
Literature
Read More
NeoGenomics Announces Closing of Recent Equity Offering and Exercise in Full of Underwriters' Over-Allotment Option
Press Release
Read More